1
|
Huang L, Li F, Neudecker J, Elsner A, Strauchmann J, Dziodzio T, Zhou H, Rueckert J. Chest wall resections for non-small cell lung cancer: a literature review. J Thorac Dis 2024; 16:4794-4806. [PMID: 39144312 PMCID: PMC11320248 DOI: 10.21037/jtd-23-774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 06/21/2024] [Indexed: 08/16/2024]
Abstract
Background and Objective The development of early screening for lung cancer has led to improved overall survival in patients with non-small cell lung cancer (NSCLC). However, the management of NSCLC patients with resectable and potentially resectable chest wall invasion (CWI) requires attention. The purpose of this review is to summarize the role of surgery (chest wall resections) in NSCLC patients with CWI. Methods A literature search and review from three databases (PubMed, Embase, and ScienceDirect) comprised the last 39 years. This review was focused on the treatment of NSCLC patients with CWI, mainly including the preoperative evaluation, principles of treatment and strategic decision-making, surgical complications, and prognostic factors. Key Content and Findings Through the collection of relevant literature on NSCLC that invades the chest wall, this narrative review describes the actual role in clinical practice and future developments of chest wall resections. Preoperative treatment requires the multidisciplinary team (MDT) team to conduct accurate clinical staging of the patient and pay attention to the patient's lymph node status and rib invasion status. The successful implementation of chest wall resection and possible chest wall reconstruction requires refined individualized treatment based on the patient's clinical characteristics, supplemented by possible postoperative systemic treatment. Conclusions Surgery plays an important role in treating NSCLC patients with CWI, and a collaborative, experienced MDT is an essential component of the successful treatment of CWI with lung cancer. In the future, more high-quality clinical research is needed to focus on CWI patients so that patients can receive more effective treatment options and better clinical prognosis.
Collapse
Affiliation(s)
- Luyu Huang
- Department of Surgery, Competence Center of Thoracic Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Feng Li
- Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Jens Neudecker
- Department of Surgery, Competence Center of Thoracic Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Aron Elsner
- Department of Surgery, Competence Center of Thoracic Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Julia Strauchmann
- Department of Surgery, Competence Center of Thoracic Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Tomasz Dziodzio
- Department of Surgery, Competence Center of Thoracic Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Haiyu Zhou
- Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
| | - Jens Rueckert
- Department of Surgery, Competence Center of Thoracic Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
2
|
Mao X, Yu C, Yin F, Xu W, Pan Y, Yang B, Huang T, Chen S, Luo W, Su T, Wu Z. IRE1α-XBP1 regulates PDK1-dependent induction of epithelial-mesenchymal transition in non-small cell lung cancer cells. Exp Cell Res 2022; 421:113376. [PMID: 36209899 DOI: 10.1016/j.yexcr.2022.113376] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Revised: 10/02/2022] [Accepted: 10/03/2022] [Indexed: 12/29/2022]
Abstract
Mounting evidence indicates that activation of unfolded protein response (UPR) and metabolic reprogramming contribute to cancer cell migration and invasion, but the molecular mechanism of pro-EMT program through a coordinated action of UPR with metabolism has not been defined. In this study, we utilized ER stress-inducing reagent, thapsigargin (TG), to induced pharmacologic ER stress in lung cancer cells. Here. We report that the branch of UPR, IRE1α-XBP1 pathway plays a pivotal role in reprogramming lung cancer cell metabolism. At the molecular level, the expression of pyruvate dehydrogenase kinase-1 (PDK-1) is directly induced by XBP1 as a consequence of UPR activation, thus facilitating aerobic glycolysis and lactate production. We also demonstrated that PDK1 serves as a downstream element of UPR activation in induction of Snail and EMT program. In addition, PDK1-induced Snail was dependent on the lactate production derived from metabolic reprogramming. Our findings reveal a critical role of lactate in pro-invasion events and establishes a direct connection between ER-stress and metabolic reprogramming in facilitating cancer cell progression.
Collapse
Affiliation(s)
- Xike Mao
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Anesthesiology, Wannan Medical College, Wuhu, 241001, China
| | - Chenxi Yu
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Feng Yin
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Wenjiao Xu
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Yonghan Pan
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Bowen Yang
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Tao Huang
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Siling Chen
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Medical Imageology, Wannan Medical College, Wuhu, 241001, China
| | - Wenge Luo
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Tianyu Su
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; School of Clinical Medicine, Wannan Medical College, Wuhu, 241001, China
| | - Zhihao Wu
- Research Laboratory of Tumor Microenvironment, Wannan Medical College, Wuhu, 241001, China; Anhui Province Key Laboratory of Active Biological Macro-molecules Research, Wannan Medical College, Wuhu, 241001, China; Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution, Wannan Medical College, Wuhu, 241001, China; Provincial Engineering Laboratory for Screening and Re-evaluation of Active Compounds of Herbal Medicines in Southern Anhui, Wannan Medical College, Wuhu, 241001, China.
| |
Collapse
|
3
|
Liao ZX, Kempson IM, Hsieh CC, Tseng SJ, Yang PC. Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer. Drug Discov Today 2021; 26:2508-2514. [PMID: 34325010 DOI: 10.1016/j.drudis.2021.07.014] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 07/03/2021] [Accepted: 07/19/2021] [Indexed: 01/13/2023]
Abstract
Targeted-therapy failure in treating nonsmall cell lung cancer (NSCLC) frequently occurs because of the emergence of drug resistance and genetic mutations. The same mutations also result in aerobic glycolysis, which further antagonizes outcomes by localized increases in lactate, an immune suppressor. Recent evidence indicates that enzymatic lowering of lactate can promote an oncolytic immune microenvironment within the tumour. Here, we review factors relating to lactate expression in NSCLC and the utility of lactate oxidase (LOX) for governing therapeutic delivery, its role in lactate oxidation and turnover, and relationships between lactate depletion and immune cell populations. The lactate-rich characteristic of NSCLC provides an exploitable property to potentially improve NSCLC outcomes and design new therapeutic strategies to integrate with conventional therapies.
Collapse
Affiliation(s)
- Zi-Xian Liao
- Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan
| | - Ivan M Kempson
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia
| | - Chia-Chen Hsieh
- Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan
| | - S-Ja Tseng
- Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 10051, Taiwan; National Taiwan University YongLin Scholar, YongLin Institute of Health, National Taiwan University, Taipei 10051, Taiwan.
| | - Pan-Chyr Yang
- Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 10051, Taiwan; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 10051, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan; Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
| |
Collapse
|